このエピソードについて
Creative Biolabs is pleased to invite Dr. Omar Abudayyeh to explore the revolutionary convergence of AI and biotechnology, unveiling breakthrough gene editing technologies, aging interventions, and AI-driven protein evolution transforming the future of medicine.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
過去のエピソードを検索
The antibody-based pharmaceuticals resource library’s Podcastの以前のエピソードを検索します。
このポッドキャストの他のエピソード
Unlock the potential of precision medicine with Creative Biolabs’ latest podcast. We dive deep into the science of drug delivery, exploring how targeted systems like nanoparticles and liposomes are revolutionizing therapy. Learn how these innovations ensure drugs reach their specific destinations, …
Unlock the potential of precision medicine with Creative Biolabs’ latest podcast. We dive deep into the science of drug delivery, exploring how targeted systems like nanoparticles and liposomes are revolutionizing therapy. Learn how these innovations ensure drugs reach their specific destinations, …
Unlock the potential of precision medicine with Creative Biolabs’ latest podcast. We dive deep into the science of drug delivery, exploring how targeted systems like nanoparticles and liposomes are revolutionizing therapy. Learn how these innovations ensure drugs reach their specific destinations, …
Unlock the potential of precision medicine with Creative Biolabs’ latest podcast. We dive deep into the science of drug delivery, exploring how targeted systems like nanoparticles and liposomes are revolutionizing therapy. Learn how these innovations ensure drugs reach their specific destinations, …
This webinar recording features the work of Dr. Carneiro's team on optimizing lipid nanoparticles (LNPs) to enhance CRISPR/Cas9 delivery and effectiveness in targeting KRAS mutations in lung tumors.
免責: このページに埋め込まれているポッドキャストとアートワークは antibodybasedpharmaceuticalsresourcelibrary からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
